CME Group Q3 Revenue Dips, Investment Income Boosts Net Profit

Ticker: CME · Form: 10-Q · Filed: 2025-10-24T00:00:00.000Z

Sentiment: mixed

Topics: Financial Services, Derivatives Trading, Exchange Operator, Market Data, Investment Income, Share Repurchase, Q3 Earnings

Related Tickers: CME, ICE, NDAQ, LSE.L

TL;DR

**CME's Q3 revenue dip is a red flag, but their investment income is a massive tailwind, making this a hold for now.**

AI Summary

CME Group Inc. reported a slight decrease in total revenues for the quarter ended September 30, 2025, falling to $1,537.6 million from $1,584.4 million in the prior year, a 3% decline. This was primarily driven by a decrease in clearing and transaction fees, which dropped from $1,297.1 million in Q3 2024 to $1,227.9 million in Q3 2025. Despite this, net income attributable to common shareholders saw a marginal decrease from $901.3 million in Q3 2024 to $896.6 million in Q3 2025. For the nine months ended September 30, 2025, total revenues increased to $4,871.9 million from $4,604.8 million, a 5.8% rise, with clearing and transaction fees up to $3,953.2 million from $3,755.9 million. Net income for the nine-month period grew to $2,889.3 million from $2,651.2 million, an 8.9% increase. Investment income significantly boosted non-operating income, rising to $1,548.7 million for the quarter and $3,959.8 million for the nine months ended September 30, 2025, compared to $1,026.8 million and $3,142.6 million respectively in the prior year. The company also initiated a $3.0 billion share repurchase program in December 2024, with $2,991.8 million remaining as of September 30, 2025.

Why It Matters

CME Group's mixed Q3 results, with a revenue dip but strong investment income, signal a complex environment for investors. The decline in clearing and transaction fees could indicate softening trading volumes or competitive pressures, impacting future core earnings. However, robust investment income highlights the company's ability to generate returns from its substantial cash and collateral holdings, a crucial factor for its financial stability and shareholder returns. For employees, stable net income suggests continued operational health, while customers might see evolving fee structures. In the broader market, CME's performance reflects trends in global derivatives trading and interest rate environments, influencing other financial market infrastructure providers.

Risk Assessment

Risk Level: medium — The risk level is medium due to a 3% decline in quarterly total revenues, specifically a $69.2 million drop in clearing and transaction fees from $1,297.1 million in Q3 2024 to $1,227.9 million in Q3 2025. This revenue sensitivity to trading activity, coupled with significant 'Other non-operating income (expense)' of -$1,396.6 million for the quarter, indicates potential volatility in earnings despite strong investment income.

Analyst Insight

Investors should monitor CME Group's core clearing and transaction fee trends closely in upcoming quarters to assess the sustainability of its primary business. While investment income provides a strong buffer, a continued decline in core revenue could signal deeper issues. Consider holding existing positions but deferring new investments until a clearer trend emerges in trading volumes.

Financial Highlights

debt To Equity
0.12
revenue
$1,537.6M
operating Margin
N/A
total Assets
$187,144.6M
total Debt
$3,421.3M
net Income
$896.6M
eps
$2.49
gross Margin
N/A
cash Position
$2,446.8M
revenue Growth
-3.0%

Revenue Breakdown

SegmentRevenueGrowth
Clearing and transaction fees$1,227.9M-5.3%
Market data and information services$202.5M+13.6%
Other$107.2M-1.7%

Key Numbers

Key Players & Entities

FAQ

What were CME Group's total revenues for the third quarter of 2025?

CME Group's total revenues for the third quarter ended September 30, 2025, were $1,537.6 million, a decrease from $1,584.4 million in the same period of 2024.

How did CME Group's net income change in Q3 2025 compared to Q3 2024?

Net income attributable to common shareholders for CME Group slightly decreased to $896.6 million in Q3 2025 from $901.3 million in Q3 2024.

What was the primary driver of CME Group's non-operating income in the nine months ended September 30, 2025?

The primary driver of CME Group's non-operating income for the nine months ended September 30, 2025, was investment income, which significantly increased to $3,959.8 million from $3,142.6 million in the prior year.

Did CME Group engage in any share repurchase activities during the nine months ended September 30, 2025?

Yes, CME Group repurchased 32,265 shares of Class A common stock for a total of $8.2 million during the nine months ended September 30, 2025, under a $3.0 billion program approved in December 2024.

What was CME Group's diluted earnings per share for the nine months ended September 30, 2025?

CME Group's diluted earnings per share for the nine months ended September 30, 2025, was $7.92, an increase from $7.27 in the same period of 2024.

How much cash and cash equivalents did CME Group have as of September 30, 2025?

As of September 30, 2025, CME Group reported cash and cash equivalents of $2,446.8 million, down from $2,892.4 million at December 31, 2024.

What were CME Group's total liabilities as of September 30, 2025?

CME Group's total liabilities as of September 30, 2025, were $158,954.3 million, a substantial increase from $110,960.1 million at December 31, 2024, largely due to performance bonds and guaranty fund contributions.

What is CME Group's outlook on competition and technological developments?

CME Group acknowledges risks from increasing competition by foreign and domestic entities and the need to keep pace with rapid technological developments, including maintaining reliability and security of enhanced functionality for customers.

How much did CME Group spend on compensation and benefits for the nine months ended September 30, 2025?

CME Group's compensation and benefits expense for the nine months ended September 30, 2025, was $665.9 million, an increase from $629.5 million in the same period of 2024.

What is the remaining authorization under CME Group's share repurchase program?

As of September 30, 2025, the remaining aggregate amount under CME Group's existing Share Repurchase Program is $2,991.8 million.

Risk Factors

Industry Context

CME Group operates in the highly competitive financial exchange and post-trade services industry. Key trends include increasing demand for data and analytics, the ongoing digitalization of financial markets, and the need for robust risk management solutions. Competition comes from other global exchanges, electronic trading platforms, and technology providers offering similar services.

Regulatory Implications

As a critical market infrastructure provider, CME Group faces stringent regulatory oversight globally. Compliance with evolving regulations, such as those related to data privacy, cybersecurity, and market integrity, is paramount and requires continuous investment and adaptation.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Clearing and transaction fees
Fees charged by CME Group for clearing trades executed on its exchanges and for the transaction itself. (This is the primary revenue driver for CME Group, and its performance directly impacts overall revenue.)
Performance bonds and guaranty fund contributions
Collateral held by CME Group to guarantee the performance of trades and mitigate counterparty risk. (Represents a significant portion of assets and liabilities, reflecting the scale of the clearinghouse operations.)
Intangible assets—trading products
Represents the value of acquired trading platforms, intellectual property, and other intangible assets related to CME's core business. (A substantial asset on the balance sheet, reflecting past acquisitions and the value of its proprietary technology and brands.)
Diluted EPS
Earnings per share calculated after accounting for all dilutive potential common shares, such as stock options and convertible securities. (A key profitability metric for shareholders, indicating how much profit is generated per outstanding share.)
Marketable securities
Investments in debt or equity securities that can be readily bought or sold in the open market. (Contributes to investment income and provides liquidity, though subject to market value fluctuations.)
Accumulated other comprehensive income (loss)
A component of shareholders' equity that includes unrealized gains and losses on certain investments and foreign currency translation adjustments. (Reflects changes in equity not recognized in net income, such as unrealized gains/losses on investments.)

Year-Over-Year Comparison

Compared to the prior year, CME Group reported a 3% decrease in total revenues for Q3 2025, primarily due to a decline in clearing and transaction fees. However, for the nine-month period, revenues grew by 5.8%. Net income saw a slight dip in the quarter but increased by 8.9% year-to-date. A significant increase in investment income provided a boost to non-operating results in both periods. The company's balance sheet shows a substantial increase in total assets and liabilities, largely driven by performance bonds and guaranty fund contributions, reflecting increased market activity or collateral requirements.

Filing Stats: 4,534 words · 18 min read · ~15 pages · Grade level 8.3 · Accepted 2025-10-24 14:07:37

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3

Financial Statements

Item 1. Financial Statements 5 Consolidated Balance Sheets at September 30, 2025 and December 31, 2024 5 Consolidated Statements of Income for the Quarters and Nine Months Ended September 30, 2025 and 2024 6 Consolidated Statements of Comprehensive Income for the Quarters and Nine Months Ended September 30, 2025 and 2024 7 Consolidated Statements of Equity for the Quarters and Nine Months Ended September 30, 2025 and 2024 8 Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 10 Notes to Unaudited Consolidated Financial Statements 12

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 24

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 33

Controls and Procedures

Item 4. Controls and Procedures 33

OTHER INFORMATION

PART II. OTHER INFORMATION 33

Legal Proceedings

Item 1. Legal Proceedings 33

Risk Factors

Item 1A. Risk Factors 33

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33

Other Information

Item 5. Other Information 33

Exhibits

Item 6. Exhibits 34

SIGNATURES

SIGNATURES 35 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Certain Terms All references to "options" or "options contracts" in the text of this document refer to options on futures contracts. Further information about CME Group and its products can be found at http://www.cmegroup.com. Information made available on our website does not constitute a part of this Quarterly Report on Form 10-Q. Information about Contract Volume and Average Rate per Contract All amounts regarding contract volume and average rate per contract are for CME Group's listed futures and options on futures contracts unless otherwise noted. Trademark Information CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc. (CME), CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group Limited. OSTTRA is a trademark of MarkitSERV Limited. Dow Jones, Dow Jones Industrial Average, S&P 500 and S&P are service and/or trademarks of Dow Jones Trademark Holdings LLC, Standard & Poor's Financial Services LLC and S&P Dow Jones Indices LLC, as the case may be, and have been licensed for use by CME. All other trademarks are the property of their respective owners.

Forward-Looking Statements

Forward-Looking Statements From time to time, in this Quarterly Report on Form 10-Q as well as in other written reports and verbal statements, we discuss our expectations regarding future performance. These forward-looking statements are identified by their use of terms and phrases such as "believe," "anticipate," "could," "estimate," "intend," "may," "plan," "expect" and similar expressions, including references to assumptions. These forward-looking statements are based on currently available competitive, financial and economic data, current expectations, estimates, forecasts and projections about the industries in which we operate and management's beliefs and assumptions. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied in any forward-looking statements. We want to caution you not to place undue reliance on any forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the factors that might affect our performance are: increasing competition by foreign and domestic entities, including increased competition from new entrants into our markets and consolidation of existing entities; our ability to keep pace with rapid technological developments, including our ability to complete the development, implementation and maintenance of the enhanced functionality required by our customers while maintaining reliability and ensuring that such technology is not vulnerable to security risks; our ability to continue introducing innovative and competitive new products and services on a timely, cost-effective basis, including through our electronic trading capabilities, and derive revenues that are commensurate with our efforts and expectations, and our ability to maintain the c

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS CME GROUP INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (dollars in millions, except par value data; shares in thousands) September 30, 2025 December 31, 2024 (unaudited) Assets Current Assets: Cash and cash equivalents $ 2,446.8 $ 2,892.4 Marketable securities 123.2 113.2 Accounts receivable, net of allowance of $9.2 and $9.0 642.9 573.1 Other current assets (includes $6.5 and $6.3 in restricted cash) 546.7 559.4 Performance bonds and guaranty fund contributions 149,041.2 98,895.4 Total current assets 152,800.8 103,033.5 Property, net of accumulated depreciation and amortization of $983.2 and $1,024.3 355.2 386.2 Intangible assets—trading products 17,175.3 17,175.3 Intangible assets—other, net 2,667.8 2,821.6 Goodwill 10,514.5 10,486.9 Other assets 3,631.0 3,543.5 Total Assets $ 187,144.6 $ 137,447.0 Liabilities and Equity Current Liabilities: Accounts payable $ 74.9 $ 79.9 Short-term debt — 749.8 Other current liabilities 471.1 2,588.8 Performance bonds and guaranty fund contributions 149,041.2 98,895.4 Total current liabilities 149,587.2 102,313.9 Long-term debt 3,421.3 2,678.2 Deferred income tax liabilities, net 5,220.1 5,246.8 Other liabilities 725.7 721.2 Total Liabilities 158,954.3 110,960.1 Shareholders' Equity: Preferred stock, $0.01 par value, 10,000 shares authorized as of September 30, 2025 and December 31, 2024; 4,584 issued and outstanding as of September 30, 2025 and December 31, 2024 — — Class A common stock, $0.01 par value, 1,000,000 shares authorized at September 30, 2025 and December 31, 2024; 359,849 and 359,602 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 3.6 3.6 Class B common stock, $0.01 par value, 3 shares authorized, issued and outstanding as of September 30, 2025 and December 31, 2024 — — Additional paid-in capital 22,436.9 22,403.0 Retained earnings 5,706.4 4,185.8 Accumulated other comprehensive income (loss) 43.4 ( 1

View on Read The Filing